BeiGene (BSP:B1GN34) Ending Cash Position : R$13,980 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is BeiGene Ending Cash Position?

BeiGene's Ending Cash Position for the quarter that ended in Mar. 2024 was R$13,980 Mil.

BeiGene's quarterly Ending Cash Position increased from Sep. 2023 (R$15,216 Mil) to Dec. 2023 (R$15,611 Mil) but then declined from Dec. 2023 (R$15,611 Mil) to Mar. 2024 (R$13,980 Mil).

BeiGene's annual Ending Cash Position declined from Dec. 2021 (R$24,785 Mil) to Dec. 2022 (R$20,326 Mil) and declined from Dec. 2022 (R$20,326 Mil) to Dec. 2023 (R$15,611 Mil).

BeiGene Ending Cash Position Historical Data

The historical data trend for BeiGene's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Ending Cash Position Chart

BeiGene Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

2,547.97

7,151.16

24,784.79

20,326.12

15,610.68

BeiGene Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															18,458.06	16,607.29	15,215.60	15,610.68	13,980.47

BeiGene Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

BeiGene's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	18986.905	+	-3376.221
	=	15,611

BeiGene's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	15865.563	+	-1885.093
	=	13,980

BeiGene Ending Cash Position Related Terms

Thank you for viewing the detailed overview of BeiGene's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

BeiGene (BSP:B1GN34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (BSP:B1GN34) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

BGNE:USA 06160:Hong Kong 49BA:Germany 688235:China

Address

c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108

Website

https://www.beigene.com

BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

BeiGene (BSP:B1GN34) Headlines

No Headlines